|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CHEMOKINES
From the Laboratory of Molecular Immunology, Rega
Institute for Medical Research, University of Leuven, Leuven, Belgium.
Chemokines are mediators in inflammatory and autoimmune disorders.
Aminoterminal truncation of chemokines results in altered specific
activities and receptor recognition patterns. Truncated forms of the
CXC chemokine interleukin (IL)-8 are more active than full-length IL-8
(1-77), provided the Glu-Leu-Arg (ELR) motif remains intact. Here, a
positive feedback loop is demonstrated between gelatinase B, a major
secreted matrix metalloproteinase (MMP-9) from neutrophils, and IL-8,
the prototype chemokine active on neutrophils. Natural human neutrophil
progelatinase B was purified to homogeneity and activated by
stromelysin-1. Gelatinase B truncated IL-8(1-77) into IL-8(7-77),
resulting in a 10- to 27-fold higher potency in neutrophil activation,
as measured by the increase in intracellular Ca++
concentration, secretion of gelatinase B, and neutrophil chemotaxis. This potentiation correlated with enhanced binding to neutrophils and
increased signaling through CXC chemokine receptor-1 (CXCR1), but it
was significantly less pronounced on a CXCR2-expressing cell line.
Three other CXC chemokines Gelatinase B, or MMP-9, belongs to the growing
family of matrix metalloproteinases (MMP). It is produced mainly by
neutrophils but is also produced by various other blood-derived cell
types Chemokines are low-molecular-mass proteins that exert potent
chemoattractant activities on leukocytes and that have effects on
angiogenesis and hematopoiesis. Based on the position of the 4 conserved cysteine residues, chemokines have been grouped into 2 major
families. CXC chemokines with one residue between the first 2 cysteines
are active on neutrophils, lymphocytes, or both. CC chemokines
with 2 adjacent cysteines are active on a variety of cell types,
including monocytes, eosinophils, basophils, and lymphocytes.12,13
Human interleukin-8 (IL-8) was identified as a potent neutrophil
chemoattractant and a granulocytosis-promoting protein,14 and it became one of the best-characterized CXC chemokines. In front of
the first cysteine residue, IL-8 contains the Glu-Leu-Arg (ELR,
amino-acid sequence in 1-letter code) motif, essential for its
neutrophil chemotactic activity. Besides the chemoattractant activity
on neutrophils, IL-8 triggers neutrophils to release the content of
some of their granules.1
Different aminoterminal variants of natural IL-8 have been identified.
For instance, IL-8(1-77) (AVLPRSAKELRCQC...), and IL-8(6-77) (SAKELRCQC...) were characterized as the major forms derived from endothelial cells or fibroblasts and leukocytes, respectively. Additional natural forms are IL-8(-2-77) (EGAVLPR...), IL-8(7-77), IL-8(8-77), and IL-8(9-77).15 In general, the shorter
forms of IL-8 are more active than the full-length form.
Other members of the CXC chemokine family, containing the ELR-motif,
are granulocyte chemotactic protein-2 (GCP-2), epithelial-cell-derived neutrophil attractant-78 (ENA-78), GRO- By analogy with IL-8, different natural truncation variants of CC
chemokines have been isolated. A monocyte chemotactic protein-2 (MCP-2)
form, which lacks 6 aminoterminal residues, was identified as a
chemokine inhibitor.22 RANTES processed by dipeptidyl
peptidase IV/CD26 lacks 2 aminoterminal residues and is a chemokine
inhibitor with potent antihuman immunodeficiency virus
activity.23 We here describe the processing of several
chemokines by the secreted metalloproteinase gelatinase B, in contrast
to the proteolytic processing by the membrane-anchored serine protease CD26.
Purification of natural gelatinase B from human neutrophils
to homogeneity
Chemokines and chemokine receptors
Human embryonic kidney (HEK) cells, transfected with CXC chemokine receptor 1 (CXCR1) or CXCR2, were kindly supplied by Dr J. M. Wang (National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD).28 HEK cells were cultured in DMEM (Life Technologies, Paisley, UK) with 10% fetal bovine serum and 800 µg/mL geneticin. Activation of gelatinase B by stromelysin-1 Stromelysin-1 (MMP-3; Biogenesis, Poole, UK) was activated with 2 mmol/L 4-aminophenylmercuric acetate (APMA) (from a 10× concentrated solution in dimethyl sulfoxide) for 5 hours at 37 °C, according to the instructions of the manufacturer. APMA was removed from the activated enzyme by ultrafiltration on membranes with a 10-kd cutoff (Millipore, Milford, MA) or by dialysis using the Slyde-A-Lyzer units (Pierce, Rockford, IL). Activation of 1 µmol/L gelatinase B was performed with 0.01 µmol/L APMA-activated stromelysin-1 for 4.5 hours in assay buffer at 37°C. The gelatinase B activity was controlled by gelatin zymography and by the conversion of the quenched fluorescent substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (Bachem, Bubendorf, Switzerland).29Digestion of chemokines with purified gelatinase B and detection of cleavage products Chemokines (4 µmol/L) were incubated with activated neutrophil gelatinase B (0.4 µmol/L) in assay buffer (see above) at 37°C for 20 hours (unless otherwise indicated). Control experiments were conducted under identical conditions without gelatinase B (but with 0.004 µmol/L activated MMP-3). Gelatinase B inhibition experiments were performed at 1.5 µmol/L chemokine and 0.2 to 0.5 µmol/L gelatinase B in the same buffer with the following individual reagents: 15 mmol/L EDTA, 2 mmol/L o-phenantrolin, 0.25 µmol/L recombinant human TIMP-1 (Calbiochem, La Jolla, CA), 2.6 µmol/L gelatinase B-inhibiting monoclonal antibody REGA-3G12,30 2 mmol/L pefabloc, 2 µg/mL E64, or 67 µg/mL aprotinin (Sigma, St Louis, MO). Chemokine cleavage products were analyzed by SDS-PAGE and separated by reverse-phase HPLC on a C8-column using a gradient of CH3CN; absorbance was recorded at 220 nm. Resultant peptides were identified by aminoterminal sequencing and mass spectrometry analysis (see below). Resultant peptide sequences are indicated by one-letter codes, and the number of the first residue derived from the mature proteinis indicated.
Mass spectrometry analysis of chemokines and chemokine cleavage products Chemokines and peptides were, if required, first desalted using the C18 ZIPTIP (Millipore) and were subsequently diluted in 50% acetonitrile/50% H2O/0.1% acetic acid. These peptide solutions were analyzed by electrospray mass spectrometry (MS) on an ion trap (Esquire-LC, Brucker, Germany) or on a quadrupole time-of-flight (QTOF-2; Micromass, Manchester, UK) apparatus. Sequencing of peptides was performed by tandem MS/MS on the ion trap apparatus. When C18 ZIPTIP was used for desalting chemokines, adducts were observed that were not present in preparations or samples prepared without the use of ZIPTIP; therefore, these adducts were not further considered. In addition, the aminoterminal sequence of specific chemokine peptides was further characterized by Edman degradation as described above.Competition for 125I-IL-8 binding to CXC receptors Purified granulocytes, HEK-CXCR1, or HEK-CXCR2 (2 × 106 cells in 200 µL) were incubated with 125I-IL-8(6-77) (10 nCi; Amersham, Uppsala, Sweden) and with various concentrations of unlabeled IL-8(1-77) or IL-8(7-77) for 2 hours at 4°C in phosphate-buffered saline with 20 g/L bovine serum albumin. After 3 subsequent washes with 1 mL phosphate-buffered saline and 20 g/L bovine serum albumin, the cell-bound radioactivity was measured with a Triathler -counter (PerkinElmer, Norwalk, CT).
Detection of intracellular Ca++ concentrations Intracellular Ca++ concentrations ([Ca++]i) were measured as described previously.18 Briefly, purified cells (107/mL) were loaded with the fluorescent indicator fura-2 (2.5 µmol/L fura-2/AM; Molecular Probes Europe BV, Leiden, The Netherlands) for 30 minutes at 37°C. After 2 washes, cells were stored on ice at 106 cells/mL for a maximum of 1.5 hours. After excitation at 340 and 380 nm, fura-2 fluorescence was detected at 510 nm in an LS50B luminescence spectrophotometer (PerkinElmer) and used for the calculation of the [Ca ++]i.In inhibition experiments, monoclonal anti-CXCR1 (R&D Systems, Minneapolis, MN) was added at a concentration of 15 µg/mL during loading of the cells with fura-2 and during subsequent storage on ice and analysis. Degranulation Aliquots of 5 × 106 purified granulocytes, derived from healthy human blood donors, were stimulated in heat-inactivated human plasma with various concentrations of IL-8(1-77) and IL-8(7-77) for 30 minutes at 37°C. Cells were removed by centrifugation, and gelatinase B in the supernatant was analyzed by gelatin substrate zymography and subsequently quantified by scanning densitometry.31 Background levels of gelatinase B-zymolysis were subtracted from the zymolysis data obtained after neutrophil stimulation with IL-8(1-77) or IL-8(7-77).Chemotaxis Chemotactic activities of IL-8(1-77) and IL-8(7-77) were compared in modified Boyden chemotaxis chambers as detailed previously.18 The chemotactic index was defined as the ratio of cells migrated toward the chemokine versus the cell numbers obtained with the excipiens.
Preparation of natural gelatinase B Human peripheral blood neutrophils were used to obtain natural gelatinase B devoid of gelatinase A contamination. Indeed, this cell type does not synthesize gelatinase A or TIMP, and it stores gelatinase B in its proenzyme form in granules. By degranulation, 3 forms of gelatinase B were released into the extracellular space: monomers, disulfide-linked homodimers, and heterodimers with NGAL.32 With the use of an NGAL monoclonal antibody, the NGAL complex was removed and an electrophoretically pure preparation of gelatinase B was obtained (Figure 1) and used for all chemokine-processing experiments.
Processing of chemokines by gelatinase B To investigate whether chemokines are processed by gelatinase B, different CXC and CC chemokines were incubated with pure activated neutrophil gelatinase B at 37°C for several time intervals (enzyme-substrate molar ratio, 1:10). Subsequently, the digestion products were identified by SDS-PAGE, aminoterminal sequencing, and mass spectrometry analysis. Two members of the CC chemokine family, RANTES and MCP-2, were not cleaved by gelatinase B (Figure 2). PF-4, an ELR-negative CXC chemokine, and GRO- , an ELR motif-containing CXC chemokine, were slowly
degraded by gelatinase B; the conversions were still incomplete after a
24-hour incubation period (Figure 2). By aminoterminal sequence
analysis, at least 2 gelatinase B cleavage sites could be identified in
GRO-, namely in front of Leu at position 7 (L7RCQCLQ...) and in front of Val at position 28 (V28KSPG...). CTAP-III was also degraded by gelatinase B
(Figures 2, 3), and multiple cleavage
sites were identified (Figure 4). To
obtain this detailed information, the CTAP-III peptides were fractionated by RP-HPLC, and the individual fractions were analyzed by
mass spectrometry (MS and MS/MS), protein sequence analysis, or both.
Incubation of natural or recombinant IL-8(1-77) with gelatinase B
resulted in the efficient removal of only 6 aminoterminal residues and,
thus, in the formation of IL-8(7-77) with A7KELR... as
the aminoterminal sequence (Figure 5,
Table 1). Both IL-8 forms, intact and
truncated, were analyzed by mass spectrometry, confirming the identity
of IL-8(1-77) and IL-8(7-77) and excluding carboxyterminal processing
of IL-8 by gelatinase B (Figure 6). IL-8(6-77) (S6AKELR...), present in the natural IL-8
preparations in addition to IL-8(1-77), was not converted by gelatinase
B to IL-8(7-77), which is consistent with the fact that gelatinase B is
not an exopeptidase (Table 1).
The kinetics of the cleavage of IL-8 and CTAP-III were also compared,
and IL-8 was found to be processed more efficiently, with IL-8(7-77)
already appearing after 1 hour of incubation and reaching 100%
conversion after 24 hours. In contrast, the first cleavage products of
CTAP-III appeared only after 2 hours, and the degradation was only
completed after 48 hours (Figure 7).
To ascertain further that the observed cleavages were performed by the metalloproteinase gelatinase B, various types of inhibition studies were performed (Figures 2,3,5). For instance, the conversions of natural or recombinant IL-8 preparations were inhibited by the matrix metalloproteinase inhibitors EDTA, o-phenantrolin, TIMP-1, and by a specific gelatinase B-inhibiting monoclonal antibody (REGA-3G12),30 but not by the inhibitors for serine (pefabloc, aprotinin) or thiol proteases (E64) (Figure 5). The IL-8 conversion was not caused by the activated stromelysin-1 (used to convert progelatinase B into active gelatinase B), because control incubations with stromelysin-1 did not result in substrate cleavage. Finally, progelatinase B in its latent form did not process IL-8, which illustrates that the activation of progelatinase B is necessary for aminoterminal clipping of IL-8. Effect of the processing by gelatinase B on the biologic activity of IL-8 Recombinant human IL-8(1-77) was converted by activated gelatinase B to IL-8(7-77), and the latter was repurified by reverse-phase HPLC. First, binding experiments were performed to compare the relative affinities of both IL-8 forms for their receptors on the surfaces of neutrophilic granulocytes. In comparison with intact IL-8(1-77), half-maximal binding of IL-8(7-77) on neutrophils was observed at concentrations more than 10 times lower (Figure 8). In addition, the biologic activities of both IL-8 forms, IL-8(1-77) and IL-8(7-77), were compared on neutrophilic granulocytes. Signal transduction by IL-8(1-77) and IL-8(7-77) through neutrophil receptors was analyzed by measuring the increase of [Ca++]i. It was found that IL-8(7-77) mobilized intracellular Ca++ at concentrations more than 20 times lower (minimal effective concentration, 0.018 nmol/L) than IL-8(1-77) (minimal effective concentration, 0.5 nmol/L) (Figure 8). Finally, degranulation and chemotaxis assays were performed on neutrophils (Figure 9). A significant release of gelatinase B was induced by IL-8(7-77) at 1 nmol/L, whereas 10 nmol/L IL-8(1-77) was required to obtain a similar effect. This difference in potency was even more pronounced in neutrophil chemotaxis assays. IL-8(7-77) induced neutrophil chemotaxis from 0.1 nmol/L onward, whereas the minimal effective concentration of IL-8(1-77) was 2.7 nmol/L. In all 4 assays (binding, [Ca++]i-increase, gelatinase B release, and chemotaxis), it was reproducibly shown that IL-8(7-77) was 14, 27, 10, and 27 times, respectively, more active on neutrophils than IL-8(1-77).
Because neutrophils have 2 IL-8 receptors, CXCR1 and
CXCR2,33 we analyzed the receptor-binding and
intracellular Ca++-mobilizing capacities of IL-8(1-77) and
IL-8(7-77) on both receptors separately. An anti-CXCR1 monoclonal
antibody was found to inhibit both IL-8 forms in the intracellular
Ca++-mobilization assay with neutrophils, showing that both
IL-8 forms use at least CXCR1 (data not shown). Binding of IL-8(1-77)
and IL-8(7-77) to CXCR1 and CXCR2 were compared on cell lines
separately transfected with either receptor (Figure
10), whereas the effects of both
ligands on intracellular Ca++-mobilization in CXCR
transfectants are documented in Figure
11. Our data on the receptor
transfectants are in line with the data on human neutrophils and
clearly show that both IL-8 forms use both receptor types. However, the
difference in binding and intracellular Ca++-mobilizing
capacity between IL-8(7-77) and IL-8(1-77) was 9-fold for CXCR1
transfectants, whereas for CXCR2 transfectants the difference (2.5- to
4-fold) between IL-8(7-77) and IL-8(1-77) was significantly less
pronounced (P < .05, Student t test) than
for CXCR1.
IL-8, the most potent neutrophil-activating chemokine, stimulates
the release of gelatinase B from neutrophils.1 Here it is
demonstrated that gelatinase B processes IL-8 and other CXC chemokines
and alters the specific activities and receptor usage. The best-known
substrates for gelatinase B are denatured collagens (gelatins).
Collagen types V and XI can also be cleaved by gelatinase B; however,
it is unclear whether gelatinase B can cleave native full-length type
IV collagen.34,35 Other extracellular matrix substrates
include aggrecan,36 link protein,37 and
elastin.38 Gelatinase B was also shown to degrade myelin
basic protein, resulting in the release of encephalitogenic
peptides.39 In addition to these structural components,
other gelatinase B substrates are functional proteins. These include
the serine-protease inhibitors We report for the first time that several CXC chemokines, but not the CC chemokines RANTES and MCP-2, are substrates for activated gelatinase B. CTAP-III was degraded by gelatinase B, and 7 different cleavage sites were identified. In contrast, IL-8(1-77) was aminoterminally truncated by gelatinase B to IL-8(7-77). The effects of this selective cleavage were reflected by the enhanced biologic activities of IL-8 and mediated more through CXCR1 and less through CXCR2. We propose that a more than 10-fold increase in neutrophil activation by truncated IL-8 has consequences not only for chemotaxis but for other processes mediated by IL-8, such as leukocytosis regulation, stem cell mobilization, and (septic) shock syndromes characterized by high circulating levels of IL-846 and gelatinase B.47 Different aminoterminally processed forms of IL-8 from natural sources have been previously described. Endothelial cells and fibroblasts produce mainly IL-8(1-77), whereas mononuclear leukocytes produce mainly IL-8(6-77).48-51 Other natural forms of IL-8 also exist, and these include IL-8(2-77), IL-8(7-77), IL-8(8-77), and IL-8(9-77).15,48 Thrombin50 and plasmin52 have been shown to convert IL-8(1-77) to IL-8(6-77), whereas proteinase-3 from neutrophils cleaves IL-8(1-77) to produce IL-8(8-77).53 In general, shorter forms of IL-8 have been shown to be more active than longer forms, provided that the ELR motif remains intact. Compared to IL-8(1-77), IL-8(6-77) was shown to be 2 to 10 times more active in binding to neutrophils and in inducing the adhesion of neutrophils, chemotaxis, and degranulation.50,53-55 IL-8(8-77) and IL-8(9-77) were shown to be even more active than IL-8(6-77), but shorter forms, lacking an intact ELR motif, are inactive.54 Here it is shown that natural and recombinant IL-8(1-77) can be
converted efficiently to IL-8(7-77) by activated neutrophil gelatinase
B. This conversion is physiologically relevant because IL-8(7-77) has
been recovered from leukocytes and fibroblasts15,48 and
because IL-8 is able to induce degranulation of the specific and
gelatinase B-containing granules from neutrophils.1,56 In
contrast, azurophilic granules In addition, IL-8(7-77) was found to be 10 to 27 times more
active on human neutrophils than IL-8(1-77), as shown in binding experiments, [Ca++]i measurements,
degranulation, and chemotaxis assays. This difference is more
pronounced than that found by Nourshargh et al55 with IL-8(6-77) in comparison with IL-8(1-77) on rabbit neutrophils, but it
is similar to the difference described by Schröder et al51 with IL-8(6-77) and IL-8(1-77) on human neutrophils.
Because neutrophils contain both IL-8 receptors, CXCR1 and CXCR2, and because it was not yet known on which receptor the shorter IL-8 forms
are more active, we also studied the Ca++-mobilizing
activities of IL-8(1-77) and IL-8(7-77) in cell lines transfected with
CXCR1 or CXCR2. In CXCR1 transfectants, the difference (9-fold) in
binding and Ca++-mobilization between IL-8(1-77) and
IL-8(7-77) is in the same order as the difference observed in
neutrophils. However, on CXCR2-transfected cells, IL-8(7-77) is only
about 2.5 to 4 times more active than IL-8(1-77). Although it is
uncertain that the binding of the chemokine to the receptors and the
signal transduction are the same in normal cells as in transfectants,
our results suggest that the aminoterminal truncation of IL-8 mainly
affects binding and signaling through CXCR1. The biologic effect of the
cleavage of IL-8 by gelatinase B may, therefore, be different for
various target cell types. Indeed, some cell types are shown to contain
predominantly one of either of the IL-8 receptors. For instance, the
chemotaxis of mast cells in response to IL-8 is mediated through CXCR2
and not through CXCR1.57 Moreover, different functions
have been ascribed to the 2 CXC chemokine-receptors on neutrophils.
This implies that the effect of the truncation of IL-8 on its activity may vary, depending on the IL-8-induced function. For instance, though
chemotaxis in response to GRO- Proteolytic activity of gelatinase B toward other chemokine substrates
was also investigated. The CXC chemokines PF-4, GRO- The neutrophil is a terminally differentiated phagocyte that contains enzymes for target cell killing and for degradation of extracellular matrix components. Activation of neutrophils by CXC chemokines such as IL-8 leads to the secretion of proteases including gelatinase B. Our results show that the predominant member of the matrix metalloproteinases in neutrophils, gelatinase B, also contributes to enhanced IL-8 activity by a positive feedback loop. This finding is not only relevant to better understand physiopathological processes such as pyogenic infections and sepsis, it is relevant for clinical applications such as stem cell mobilization, in which both gelatinase B65 and IL-866,67 are involved.
We thank Sofie Struyf for her scientific contributions and René Conings, Jean-Pierre Lenaerts, and Willy Put for experimental help. We thank the F.W.O.-Vlaanderen for its support in acquiring the mass spectrometry equipment.
Submitted October 11, 1999; accepted June 6, 2000.
Supported by the Fortis Insurances AB, the Charcot Foundation, the "Geconcerteerde OnderzoeksActies," and the National Fund for Scientific Research (F.W.O.-Vlaanderen), Belgium. P.V.d.S. is a research assistant and P.P. is a postdoctoral fellow of the F.W.O.-Vlaanderen.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ghislain Opdenakker, Laboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
1. Masure S, Proost P, Van Damme J, Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase: release by the activating peptide interleukin-8. Eur J Biochem. 1991;198:391-398[Medline] [Order article via Infotrieve]. 2. Vu TH, Werb Z. Gelatinase B: structure, regulation, and function. In: Parks WC,Mecham RP, eds. Matrix Metalloproteinases. St. Louis: Academic; 1998:115-148. 3. Opdenakker G, Fibbe WE, Van Damme J. The molecular basis of leukocytosis. Immunol Today. 1998;19:182-189[Medline] [Order article via Infotrieve]. 4. Okada Y, Naka K, Kawamura K, et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implication for bone resorption. Lab Invest. 1995;72:311-322[Medline] [Order article via Infotrieve]. 5. Vu TH, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998;93:411-422[Medline] [Order article via Infotrieve]. 6. Stetler-Stevenson WG, Liotta LA, Kleiner DA Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and cancer metastasis. FASEB J. 1993;7:1434-1441[Abstract].
7.
Hua J, Muschel RJ.
Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system.
Cancer Res.
1996;56:5279-5284 8. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today. 1994;15:103-107[Medline] [Order article via Infotrieve]. 9. Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteinases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol. 1999;94:1-14[Medline] [Order article via Infotrieve]. 10. Imper V, Van Wart HE. Substrate specificity and mechanisms of substrate recognition of the matrix metalloproteinases. In: Parks WC,Mecham RP, eds. Matrix Metalloproteinases. St. Louis: Academic; 1998:219-242. 11. Opdenakker G, Masure S, Grillet B, Van Damme J. Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res. 1991;10:317-324[Medline] [Order article via Infotrieve].
12.
Rollins BJ.
Chemokines.
Blood.
1997;90:909-928
13.
Luster AD.
Chemokines 14. Van Damme J, Van Beeumen J, Opdenakker G, Billiau A. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity. J Exp Med. 1988;167:1384-1386. 15. Van Damme J, Decock B, Conings R, Lenaerts JP, Opdenakker G, Billiau A. The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin 8. Eur J Immunol. 1989;19:1189-1194[Medline] [Order article via Infotrieve].
16.
Walz A, Baggiolini M.
Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases.
J Exp Med.
1990;171:449-454 17. Brandt E, Van Damme J, Flad HD. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III. Cytokine. 1991;3:311-321[Medline] [Order article via Infotrieve].
18.
Wuyts A, Govaerts C, Struyf S, et al.
Isolation of the CXC chemokines ENA-78, GRO 19. Nufer O, Corbett M, Walz A. Amino-terminal processing of chemokine ENA-78 regulates biological activity. Biochemistry. 1999;38:638-642.
20.
Petersen F, Ludwig A, Flad H-D, Brandt E.
TNF-
21.
Gentilini G, Kirschbaum NE, Augustine JA, Aster RH, Visentin GP.
Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1).
Blood.
1999;93:25-32
22.
Proost P, Struyf S, Couvreur M, et al.
Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor.
J Immunol.
1998;160:4034-4041
23.
Proost P, De Meester I, Schols D, et al.
Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV: conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.
J Biol Chem.
1998;273:7222-7227 24. Strong RK, Bratt T, Cowland JB, Borregaard N, Wiberg FC, Ewald AJ. Expression, purification, crystallization and crystallographic characterization of dimeric and monomeric human neutrophil gelatinase associated lipocalin. Acta Cryst. 1998;D54:93-95. 25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254[Medline] [Order article via Infotrieve]. 26. Proost P, Wuyts A, Conings R, Lenaerts J-P, Put W, Van Damme J. Purification and identification of natural chemokines. Methods. 1996;10:82-92[Medline] [Order article via Infotrieve]. 27. Van Coillie E, Proost P, Van Aelst I, et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry. 1998;37:12672-12680[Medline] [Order article via Infotrieve]. 28. Ben-Baruch A, Bengali K, Tani K, Xu L, Oppenheim JJ, Wang JM. IL-8 and NAP-2 differ in their capacities to bind and chemoattract 293 cells transfected with either IL-8 receptor type A or type B. Cytokine. 1997;9:37-45[Medline] [Order article via Infotrieve]. 29. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992;296:263-266[Medline] [Order article via Infotrieve]. 30. Paemen L, Martens E, Masure S, Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem. 1995;234:759-765[Medline] [Order article via Infotrieve]. 31. Masure S, Billiau A, Van Damme J, Opdenakker G. Human hepathoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim Biophys Acta. 1990;1054:317-325[Medline] [Order article via Infotrieve].
32.
Kjeldsen L, Johnson AH, Sengelov H, Borregaard N.
Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase.
J Biol Chem.
1993;268:10425-10432 33. Chuntharapai A, Lee J, Hébert CA, Kim KJ. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol. 1994;153:5682-5688[Abstract].
34.
Mackay AR, Hartzler JL, Pelina MD, Thorgeirsson UP.
Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen.
J Biol Chem.
1990;265:21929-21934 35. Hoyhtya M, Turpeenniemi-Hujanen T, Stetler-Stevenson W, Krutzsch H, Tryggvason K, Liotta LA. Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. FEBS Lett. 1988;233:109-113[Medline] [Order article via Infotrieve].
36.
Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA.
The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B.
J Biol Chem.
1992;267:19470-19474 37. Nguyen Q, Murphy G, Hughes CE, Mort JS, Roughley PJ. Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem J. 1993;295:595-598.
38.
Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG.
Human 92- and 72-kilodalton type IV collagenases are elastases.
J Biol Chem.
1991;266:7870-7885 39. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun. 1993;192:1175-1181[Medline] [Order article via Infotrieve].
40.
Desrochers PE, Mookhtiar K, Van Wart HE, Hasty KA, Weiss SJ.
Proteolytic inactivation of
41.
Sires UI, Murphy G, Baragi VM, Fliszar CJ, Welgus HG, Senior RM.
Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of 42. Backstrom JR, Tokes ZA. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem. 1995;64:1312-1318[Medline] [Order article via Infotrieve].
43.
Mehul B, Bawumia S, Martin SR, Hughes RC.
Structure of baby hamster kidney carbohydrate-binding protein CBP30, an S-type animal lectin.
J Biol Chem.
1994;269:18250-18258 44. Ochieng J, Fridman R, Nangia-Makker P, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry. 1994;33:14109-14114[Medline] [Order article via Infotrieve].
45.
Schönbeck U, Mach F, Libby P.
Generation of biologically active IL-1
46.
Hack CE, Hart M, van Schijndel RJ, et al.
Interleukin-8 in sepsis: relation to shock and inflammatory mediators.
Infect Immun.
1992;60:2835-2842 47. Paemen L, Jansen PM, Proost P, et al. Induction of gelatinase B and MCP-2 in baboons during sublethal and lethal bacteraemia. Cytokine. 1997;9:412-415[Medline] [Order article via Infotrieve].
48.
Van Damme J, Van Beeumen J, Conings R, Decock B, Billiau A.
Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of 49. Yoshimura T, Robinson EA, Appella E, et al. Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence. Mol Immunol. 1989;26:87-93[Medline] [Order article via Infotrieve]. 50. Hébert CA, Luscinskas FW, Kiely JM, et al. Endothelial and leukocyte forms of IL-8: conversion by thrombin and interactions with neutrophils. J Immunol. 1990;145:3033-3040[Abstract].
51.
Schröder JM, Sticherling M, Henneicke HH, Preissner WC, Christophers E.
IL-1 52. Nakagawa H, Hatakeyama S, Ikesue A, Miyai H. Generation of interleukin-8 by plasmin from AVLPR-interleukin-8, the human fibroblast-derived neutrophil chemotactic factor. FEBS Lett. 1991;282:412-414[Medline] [Order article via Infotrieve]. 53. Padrines M, Wolf M, Walz A, Baggiolini M. Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. FEBS Lett. 1994;352:231-235[Medline] [Order article via Infotrieve].
54.
Clark-Lewis I, Schumacher C, Baggiolini M, Moser B.
Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs: critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities.
J Biol Chem.
1991;266:23128-23134 55. Nourshargh S, Perkins JA, Showell HJ, Matsushima K, Williams TJ, Collins PD. A comparative study of the neutrophil stimulatory activity in vitro and pro-inflammatory properties in vivo of 72 amino acid and 77 amino acid IL-8. J Immunol. 1992;148:106-111[Abstract].
56.
Brandt E, Petersen F, Flad HD.
Recombinant tumor necrosis factor-
57.
Nilsson G, Mikovits JA, Metcalfe DD, Taub DD.
Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/interleukin-8RB.
Blood.
1999;93:2791-2797 58. Hammond ME, Lapointe GR, Feucht PH, et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol. 1995;155:1428-1433[Abstract]. 59. Chuntharapai A, Kim KJ. Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J Immunol. 1995;155:2587-2594[Abstract]. 60. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Both interleukin-8 receptors independently mediate chemotaxis: Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2. FEBS Lett. 1994;341:187-192[Medline] [Order article via Infotrieve].
61.
Jones SA, Wolf M, Qin S, Mackay CR, Baggiolini M.
Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2.
Proc Natl Acad Sci U S A.
1996;93:6682-6686 62. Jones SA, Moser B, Thelen M. A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2: chemokine mediated activation of p42/p44 MAP-kinase (ERK-2). FEBS Lett. 1995;364:211-214[Medline] [Order article via Infotrieve].
63.
Cummings CJ, Martin TR, Frevert CW, et al.
Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis.
J Immunol.
1999;162:2341-2346
64.
Khandaker MH, Mitchell G, Xu L, et al.
Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-
65.
Pruijt JFM, Fibbe WE, Laterveer L, et al.
Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against gelatinase B (MMP-9).
Proc Natl Acad Sci U S A.
1999;96:10863-10868
66.
Laterveer L, Lindley IJ, Heemskerk DP, et al.
Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8.
Blood.
1996;87:781-788
67.
Watanabe T, Kawano Y, Kanamaru S, et al.
Endogenous interleukin-8 (IL-8) surges in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization.
Blood.
1999;93:1157-1163
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. Loos, G. Opdenakker, J. Van Damme, and P. Proost Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation Haematologica, October 1, 2009; 94(10): 1346 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Ardi, P. E. Van den Steen, G. Opdenakker, B. Schweighofer, E. I. Deryugina, and J. P. Quigley Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway J. Biol. Chem., September 18, 2009; 284(38): 25854 - 25866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Page, J. R. Ledford, P. Zhou, and M. Wills-Karp A TLR2 Agonist in German Cockroach Frass Activates MMP-9 Release and Is Protective against Allergic Inflammation in Mice J. Immunol., September 1, 2009; 183(5): 3400 - 3408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lukkarinen, A. Hogmalm, U. Lappalainen, and K. Bry Matrix Metalloproteinase-9 Deficiency Worsens Lung Injury in a Model of Bronchopulmonary Dysplasia Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Fiedler, A. B. Leichtle, J. Kase, S. Baumann, U. Ceglarek, K. Felix, T. Conrad, H. Witzigmann, A. Weimann, C. Schutte, et al. Serum Peptidome Profiling Revealed Platelet Factor 4 as a Potential Discriminating Peptide Associated with Pancreatic Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3812 - 3819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Vaisar, S. Y. Kassim, I. G. Gomez, P. S. Green, S. Hargarten, P. J. Gough, W. C. Parks, C. L. Wilson, E. W. Raines, and J. W. Heinecke MMP-9 Sheds the {beta}2 Integrin Subunit (CD18) from Macrophages Mol. Cell. Proteomics, May 1, 2009; 8(5): 1044 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. MacLauchlan, E. A. Skokos, N. Meznarich, D. H. Zhu, S. Raoof, J. M. Shipley, R. M. Senior, P. Bornstein, and T. R. Kyriakides Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9 J. Leukoc. Biol., April 1, 2009; 85(4): 617 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Manicone, T. P. Birkland, M. Lin, T. Betsuyaku, N. van Rooijen, J. Lohi, J. Keski-Oja, Y. Wang, S. J. Skerrett, and W. C. Parks Epilysin (MMP-28) Restrains Early Macrophage Recruitment in Pseudomonas aeruginosa Pneumonia J. Immunol., March 15, 2009; 182(6): 3866 - 3876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-K. Ito, G. Ishii, S. Saito, K. Yano, A. Hoshino, T. Suzuki, and A. Ochiai Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells Blood, March 5, 2009; 113(10): 2363 - 2369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tamassia, V. Le Moigne, M. Rossato, M. Donini, S. McCartney, F. Calzetti, M. Colonna, F. Bazzoni, and M. A. Cassatella Activation of an Immunoregulatory and Antiviral Gene Expression Program in Poly(I:C)-Transfected Human Neutrophils J. Immunol., November 1, 2008; 181(9): 6563 - 6573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Dean, J. H. Cox, C. L. Bellac, A. Doucet, A. E. Starr, and C. M. Overall Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx Blood, October 15, 2008; 112(8): 3455 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Welsh, P.H. Whincup, O. Papacosta, S.G. Wannamethee, L. Lennon, A. Thomson, A. Rumley, and G.D.O. Lowe Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men QJM, October 1, 2008; 101(10): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Proost, T. Loos, A. Mortier, E. Schutyser, M. Gouwy, S. Noppen, C. Dillen, I. Ronsse, R. Conings, S. Struyf, et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation J. Exp. Med., September 1, 2008; 205(9): 2085 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Focosi, R. E. Kast, S. Galimberti, and M. Petrini Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex J. Leukoc. Biol., August 1, 2008; 84(2): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Cox, R. A. Dean, C. R. Roberts, and C. M. Overall Matrix Metalloproteinase Processing of CXCL11/I-TAC Results in Loss of Chemoattractant Activity and Altered Glycosaminoglycan Binding J. Biol. Chem., July 11, 2008; 283(28): 19389 - 19399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lin, P. Jackson, A. M. Tester, E. Diaconu, C. M. Overall, J. E. Blalock, and E. Pearlman Matrix Metalloproteinase-8 Facilitates Neutrophil Migration through the Corneal Stromal Matrix by Collagen Degradation and Production of the Chemotactic Peptide Pro-Gly-Pro Am. J. Pathol., July 1, 2008; 173(1): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Foronjy, T. Nkyimbeng, A. Wallace, J. Thankachen, Y. Okada, V. Lemaitre, and J. D'Armiento Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1149 - L1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gaggar, P. L. Jackson, B. D. Noerager, P. J. O'Reilly, D. B. McQuaid, S. M. Rowe, J. P. Clancy, and J. E. Blalock A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation J. Immunol., April 15, 2008; 180(8): 5662 - 5669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Jovanovic, A.-S. Dugast, J.-M. Heslan, J. Ashton-Chess, M. Giral, N. Degauque, A. Moreau, A. Pallier, E. Chiffoleau, D. Lair, et al. Implication of Matrix Metalloproteinase 7 and the Noncanonical Wingless-Type Signaling Pathway in a Model of Kidney Allograft Tolerance Induced by the Administration of Anti-Donor Class II Antibodies J. Immunol., February 1, 2008; 180(3): 1317 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Doz, N. Noulin, E. Boichot, I. Guenon, L. Fick, M. Le Bert, V. Lagente, B. Ryffel, B. Schnyder, V. F. J. Quesniaux, et al. Cigarette Smoke-Induced Pulmonary Inflammation Is TLR4/MyD88 and IL-1R1/MyD88 Signaling Dependent J. Immunol., January 15, 2008; 180(2): 1169 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Van Lint and C. Libert Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation J. Leukoc. Biol., December 1, 2007; 82(6): 1375 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. B. Levashova, N. Sharma, O. A. Timofeeva, J. S. Dome, and A. O. Perantoni ELR+-CXC Chemokines and Their Receptors in Early Metanephric Development J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2359 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gaggar, Y. Li, N. Weathington, M. Winkler, M. Kong, P. Jackson, J. E. Blalock, and J. P. Clancy Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L96 - L104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Monteagudo, J M Martin, E Jorda, and A Llombart-Bosch CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors J. Clin. Pathol., June 1, 2007; 60(6): 596 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Sheehan, C. Zhou, I. Gravanis, A. D. Rogove, Y.-P. Wu, D. F. Bogenhagen, and S. E. Tsirka Proteolytic Activation of Monocyte Chemoattractant Protein-1 by Plasmin Underlies Excitotoxic Neurodegeneration in Mice J. Neurosci., February 14, 2007; 27(7): 1738 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Greenlee, Z. Werb, and F. Kheradmand Matrix Metalloproteinases in Lung: Multiple, Multifarious, and Multifaceted Physiol Rev, January 1, 2007; 87(1): 69 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iwata, M. Pillai, A. Ramakrishnan, R. C. Hackman, H. J. Deeg, G. Opdenakker, and B. Torok-Storb Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity Blood, January 1, 2007; 109(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Lim, W. Lu, O. Hartley, and A. L. DeVico N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant J. Leukoc. Biol., December 1, 2006; 80(6): 1395 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Webster and S. M. Crowe Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases J. Leukoc. Biol., November 1, 2006; 80(5): 1052 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Lockwood, F. Arcuri, P. Toti, C. D. Felice, G. Krikun, S. Guller, L. F. Buchwalder, and F. Schatz Tumor Necrosis Factor-{alpha} and Interleukin-1{beta} Regulate Interleukin-8 Expression in Third Trimester Decidual Cells: Implications for the Genesis of Chorioamnionitis Am. J. Pathol., October 1, 2006; 169(4): 1294 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Birrell, S. Wong, A. Dekkak, J. De Alba, S. Haj-Yahia, and M. G. Belvisi Role of Matrix Metalloproteinases in the Inflammatory Response in Human Airway Cell-Based Assays and in Rodent Models of Airway Disease J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 741 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Lee, K. H. Min, S. R. Kim, S. J. Park, H. S. Park, G. Y. Jin, and Y. C. Lee Vascular Endothelial Growth Factor Modulates Matrix Metalloproteinase-9 Expression in Asthma Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 161 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Van den Steen, I. Van Aelst, V. Hvidberg, H. Piccard, P. Fiten, C. Jacobsen, S. K. Moestrup, S. Fry, L. Royle, M. R. Wormald, et al. The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors J. Biol. Chem., July 7, 2006; 281(27): 18626 - 18637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Atkinson and S. D. Shapiro Neutrophil-mediated eosinophil transmigration: parting the red sea or leaving bread crumbs. Am. J. Respir. Cell Mol. Biol., June 1, 2006; 34(6): 645 - 646. [Full Text] [PDF]
|
|
|
|
|
|
I. Kikuchi, S. Kikuchi, T. Kobayashi, K. Hagiwara, Y. Sakamoto, M. Kanazawa, and M. Nagata Eosinophil Trans-Basement Membrane Migration Induced by Interleukin-8 and Neutrophils Am. J. Respir. Cell Mol. Biol., June 1, 2006; 34(6): 760 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hu and L. B. Ivashkiv Costimulation of Chemokine Receptor Signaling by Matrix Metalloproteinase-9 Mediates Enhanced Migration of IFN-{alpha} Dendritic Cells J. Immunol., May 15, 2006; 176(10): 6022 - 6033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Agrawal, P. Anderson, M. Durbeej, N. van Rooijen, F. Ivars, G. Opdenakker, and L. M. Sorokin Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis J. Exp. Med., April 17, 2006; 203(4): 1007 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Frake, H. E. Smith, L.-F. Chen, and W. L. Biffl Prestorage Leukoreduction Prevents Accumulation of Matrix Metalloproteinase 9 in Stored Blood Arch Surg, April 1, 2006; 141(4): 396 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ahmad, T. Takino, H. Miyamori, T. Yoshizaki, M. Furukawa, and H. Sato Cleavage of Amyloid-{beta} Precursor Protein (APP) by Membrane-Type Matrix Metalloproteinases. J. Biochem., March 1, 2006; 139(3): 517 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Merck, C. Gaillard, M. Scuiller, P. Scapini, M. A. Cassatella, G. Trinchieri, and E. E. M. Bates Ligation of the FcR{gamma} Chain-Associated Human Osteoclast-Associated Receptor Enhances the Proinflammatory Responses of Human Monocytes and Neutrophils. J. Immunol., March 1, 2006; 176(5): 3149 - 3156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P T G Elkington and J S Friedland Matrix metalloproteinases in destructive pulmonary pathology Thorax, March 1, 2006; 61(3): 259 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Bendre, A. G. Margulies, B. Walser, N. S. Akel, S. Bhattacharrya, R. A. Skinner, F. Swain, V. Ramani, K. S. Mohammad, L. L. Wessner, et al. Tumor-Derived Interleukin-8 Stimulates Osteolysis Independent of the Receptor Activator of Nuclear Factor-{kappa}B Ligand Pathway Cancer Res., December 1, 2005; 65(23): 11001 - 11009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Owen Proteinases and Oxidants as Targets in the Treatment of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 373 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Simpson, R. J. Scott, M. J. Boyle, and P. G. Gibson Differential Proteolytic Enzyme Activity in Eosinophilic and Neutrophilic Asthma Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 559 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Lim, J. M. Burns, W. Lu, and A. L. DeVico Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5 J. Leukoc. Biol., August 1, 2005; 78(2): 442 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Gidday, Y. G. Gasche, J.-C. Copin, A. R. Shah, R. S. Perez, S. D. Shapiro, P. H. Chan, and T. S. Park Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H558 - H568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chakrabarti and K. D. Patel Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils J. Leukoc. Biol., July 1, 2005; 78(1): 279 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Taggart, C. M. Greene, T. P. Carroll, S. J. O'Neill, and N. G. McElvaney Elastolytic Proteases: Inflammation Resolution and Dysregulation in Chronic Infective Lung Disease Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1070 - 1076. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bellehumeur, T. Collette, R. Maheux, J. Mailloux, M. Villeneuve, and A. Akoum Increased soluble interleukin-1 receptor type II proteolysis in the endometrium of women with endometriosis Hum. Reprod., May 1, 2005; 20(5): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes Mediators of Chronic Obstructive Pulmonary Disease Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, T. Aoki, Y. Mori, M. Ahmad, H. Miyamori, T. Takino, and H. Sato Cleavage of Lumican by Membrane-Type Matrix Metalloproteinase-1 Abrogates This Proteoglycan-Mediated Suppression of Tumor Cell Colony Formation in Soft Agar Cancer Res., October 1, 2004; 64(19): 7058 - 7064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Rao, T. V. Betz, D. J. Lamont, M. B. Kim, S. K. Shaw, R. M. Froio, F. Baleux, F. Arenzana-Seisdedos, R. Alon, and F. W. Luscinskas Elastase Release by Transmigrating Neutrophils Deactivates Endothelial-bound SDF-1{alpha} and Attenuates Subsequent T Lymphocyte Transendothelial Migration J. Exp. Med., September 20, 2004; 200(6): 713 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gouwy, S. Struyf, J. Catusse, P. Proost, and J. Van Damme Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration J. Leukoc. Biol., July 1, 2004; 76(1): 185 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Tam, C. J. Morrison, Y. I. Wu, M. S. Stack, and C. M. Overall Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates PNAS, May 4, 2004; 101(18): 6917 - 6922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Proost, S. Verpoest, K. V. de Borne, E. Schutyser, S. Struyf, W. Put, I. Ronsse, B. Grillet, G. Opdenakker, and J. V. Damme Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-{gamma} in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids J. Leukoc. Biol., May 1, 2004; 75(5): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Rosario, S. W. Waldo, S. A. Becker, and G. W. Schmid-Schonbein Pancreatic Trypsin Increases Matrix Metalloproteinase-9 Accumulation and Activation during Acute Intestinal Ischemia-Reperfusion in the Rat Am. J. Pathol., May 1, 2004; 164(5): 1707 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Hensbergen, D. Verzijl, C. I. A. Balog, R. Dijkman, R. C. van der Schors, E. M. H. van der Raaij-Helmer, M. J. A. van der Plas, R. Leurs, A. M. Deelder, M. J. Smit, et al. Furin Is a Chemokine-modifying Enzyme: IN VITRO AND IN VIVO PROCESSING OF CXCL10 GENERATES A C-TERMINALLY TRUNCATED CHEMOKINE RETAINING FULL ACTIVITY J. Biol. Chem., April 2, 2004; 279(14): 13402 - 13411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. Witherden, E. J. Vanden Bon, P. Goldstraw, C. Ratcliffe, U. Pastorino, and T. D. Tetley Primary Human Alveolar Type II Epithelial Cell Chemokine Release: Effects of Cigarette Smoke and Neutrophil Elastase Am. J. Respir. Cell Mol. Biol., April 1, 2004; 30(4): 500 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Conant, C. St. Hillaire, H. Nagase, R. Visse, D. Gary, N. Haughey, C. Anderson, J. Turchan, and A. Nath Matrix Metalloproteinase 1 Interacts with Neuronal Integrins and Stimulates Dephosphorylation of Akt J. Biol. Chem., February 27, 2004; 279(9): 8056 - 8062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. McMillan, J. Kearley, J. D. Campbell, X.-W. Zhu, K. Y. Larbi, J. M. Shipley, R. M. Senior, S. Nourshargh, and C. M. Lloyd Matrix Metalloproteinase-9 Deficiency Results in Enhanced Allergen-Induced Airway Inflammation J. Immunol., February 15, 2004; 172(4): 2586 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Strasly, G. Doronzo, P. Capello, D. Valdembri, M. Arese, S. Mitola, P. Moore, G. Alessandri, M. Giovarelli, and F. Bussolino CCL16 activates an angiogenic program in vascular endothelial cells Blood, January 1, 2004; 103(1): 40 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Doubrovina, M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma J. Immunol., December 15, 2003; 171(12): 6891 - 6899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gross, C. A. Amella, L. Pompucci, G. Franchin, B. Sherry, and H. Schmidtmayerova Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection J. Leukoc. Biol., November 1, 2003; 74(5): 781 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Endo, T. Takino, H. Miyamori, H. Kinsen, T. Yoshizaki, M. Furukawa, and H. Sato Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration J. Biol. Chem., October 17, 2003; 278(42): 40764 - 40770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Owen, Z. Hu, B. Barrick, and S. D. Shapiro Inducible Expression of Tissue Inhibitor of Metalloproteinases-Resistant Matrix Metalloproteinase-9 on the Cell Surface of Neutrophils Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): 283 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Leonardi, P. Brun, G. Abatangelo, M. Plebani, and A. G. Secchi Tear Levels and Activity of Matrix Metalloproteinase (MMP)-1 and MMP-9 in Vernal Keratoconjunctivitis Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3052 - 3058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nelissen, E. Martens, P. E. Van Den Steen, P. Proost, I. Ronsse, and G. Opdenakker Gelatinase B/matrix metalloproteinase-9 cleaves interferon-{beta} and is a target for immunotherapy Brain, June 1, 2003; 126(6): 1371 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wolf, I. Clark-Lewis, C. Buri, H. Langen, M. Lis, and L. Mazzucchelli Cathepsin D Specifically Cleaves the Chemokines Macrophage Inflammatory Protein-1{alpha}, Macrophage Inflammatory Protein-1{beta}, and SLC That Are Expressed in Human Breast Cancer Am. J. Pathol., April 1, 2003; 162(4): 1183 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Atkinson and R. M. Senior Matrix Metalloproteinase-9 in Lung Remodeling Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 12 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. McQuibban, J.-H. Gong, J. P. Wong, J. L. Wallace, I. Clark-Lewis, and C. M. Overall Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo Blood, July 30, 2002; 100(4): 1160 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gouwy, S. Struyf, F. Mahieu, W. Put, P. Proost, and J. Van Damme The Unique Property of the CC Chemokine Regakine-1 to Synergize with Other Plasma-Derived Inflammatory Mediators in Neutrophil Chemotaxis Does Not Reside in Its NH2-Terminal Structure Mol. Pharmacol., July 1, 2002; 62(1): 173 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schutyser, S. Struyf, P. Proost, G. Opdenakker, G. Laureys, B. Verhasselt, L. Peperstraete, I. Van de Putte, A. Saccani, P. Allavena, et al. Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma J. Biol. Chem., June 28, 2002; 277(27): 24584 - 24593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. M. Pruijt, P. Verzaal, R. van Os, E.-J. F. M. de Kruijf, M. L. J. van Schie, A. Mantovani, A. Vecchi, I. J. D. Lindley, R. Willemze, S. Starckx, et al. Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice PNAS, April 30, 2002; 99(9): 6228 - 6233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. VAN DEN STEEN, P. PROOST, B. GRILLET, D. D. BRAND, A. H. KANG, J. VAN DAMME, and G. OPDENAKKER Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis FASEB J, March 1, 2002; 16(3): 379 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Cuello, D Wakefield, and N Di Girolamo Neutrophil accumulation correlates with type IV collagenase/gelatinase activity in endotoxin induced uveitis Br J Ophthalmol, March 1, 2002; 86(3): 290 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Nelissen, I. Ronsse, J. Van Damme, and G. Opdenakker Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta J. Leukoc. Biol., January 1, 2002; 71(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Proost, E. Schutyser, P. Menten, S. Struyf, A. Wuyts, G. Opdenakker, M. Detheux, M. Parmentier, C. Durinx, A.-M. Lambeir, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties Blood, December 15, 2001; 98(13): 3554 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. McQuibban, G. S. Butler, J.-H. Gong, L. Bendall, C. Power, I. Clark-Lewis, and C. M. Overall Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1 J. Biol. Chem., November 16, 2001; 276(47): 43503 - 43508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Coillie, I. Van Aelst, A. Wuyts, R. Vercauteren, R. Devos, C. De Wolf-Peeters, J. Van Damme, and G. Opdenakker Tumor Angiogenesis Induced by Granulocyte Chemotactic Protein-2 as a Countercurrent Principle Am. J. Pathol., October 1, 2001; 159(4): 1405 - 1414. [Abstract] [Full Text]
|
|
|
|
|
|
G. Opdenakker, P. E. Van den Steen, B. Dubois, I. Nelissen, E. Van Coillie, S. Masure, P. Proost, and J. Van Damme Gelatinase B functions as regulator and effector in leukocyte biology J. Leukoc. Biol., June 1, 2001; 69(6): 851 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yan and M. A. Moses A Case of Tumor Betrayal : Biphasic Effects of TIMP-1 on Burkitt's Lymphoma Am. J. Pathol., April 1, 2001; 158(4): 1185 - 1190. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
and leaves RANTES and MCP-2 intact
Top
Abstract
Introduction
, GRO-
, incubation with stromelysin-1 only; +, incubation with
activated gelatinase B. Respective inhibitors are indicated at the top
of each lane.
